At this year’s RSNA, iCAD launched several new CAD analysis and clinical decision support solutions that work in combination with CT and MRI imaging modalities.
The company displayed its FDA-approved SpectraLook and VividLook, which use algorithms that generate colorized MRI images and enhancement curves on a pixel-by-pixel basis, providing radiologists with contrast kinetic assessment of lesions in the breast and prostate.
VeraLook is a CAD solution for virtual colonoscopy (CTC) designed to aid radiologists in the detection of polyps during their review of CTC exams. Stacey Stevens, senior vice president (VP) of marketing and strategy for iCAD, told Health Imaging News that the company expects to receive its CE Mark for VeraLook by January 2009.
In order to seek FDA approval for VeraLook, Stevens said that iCAD initiated a “large-scale” clinical trial, designed with the FDA to submit its application. Along with other endpoints, the trial will seek to uncover the increased sensitivity to polyps reading with CAD, compared to reading alone, Marc Fillerman, VP of global marketing at iCAD, told Health Imaging News.
CADvue is an MRI image review, analysis and BI-RADS compatible reporting solution providing contrast enhancement curves, 3D images and quantification of lesion parameters, according to the company. CADvue’s automation of manual steps provides a reduction in the time required to generate curves and streamlines radiologist’s work flow and diagnosis, according to the company.
iCAD also demonstrated elements of their next generation SecondLook Digital CAD solution currently under development. Advances shown will include performance improvements, software enhancements, and new “lesion metrics” that provide insight into CAD’s decision making process.